|Dr. Seth Lederman||Co-Founder, Pres, CEO & Chairman||472.5k||N/A||1958|
|Mr. Bradley Saenger||CFO & Treasurer||335k||N/A||1974|
|Dr. Gregory M. Sullivan||Chief Medical Officer & Sec.||335k||N/A||1966|
|Mrs. Jessica Edgar Morris||Chief Operating Officer||N/A||N/A||N/A|
|Dr. Ronald R. Notvest Ph.D., MBA||Exec. VP of Commercial Planning and Devel.||N/A||N/A||N/A|
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense. Its lead product candidate is TNX-102 SL or Tonmya that is designed as a bedtime administration for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population. The company is also developing TNX-601 (tianeptine oxalate), a pre-investigational new drug (pre-IND) application stage, designed as a daytime administration for the treatment of PTSD; and TNX-801, a live synthetic version of horsepox virus at the pre-IND application stage. Its product pipeline also includes TNX-301, a potential treatment for AUD; and TNX-701, a biodefense development program for protection from radiation injury. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.
Tonix Pharmaceuticals Holding Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.